Predict your next investment

AN2 Therapeutics company logo
HEALTHCARE | Drug Discovery
an2therapeutics.com

See what CB Insights has to offer

Executives

3

Board of Directors

1

AN2 Therapeutics Board of Director

1 Board of directors

AN2 Therapeutics has 1 board of directors, including Joe Zakrzewski.

Name

Firm

Work History

Other Seats

Joe Zakrzewski

Mr. Zakrzewski has over 25 years of experience as an executive in the biotechnology and pharmaceutical industry. He currently serves on the Board of Directors of publicly held companies Acceleron Pharmaceuticals, Amarin Pharmaceuticals, Onxeo S.A., and Sangamo Therapeutics. Mr Zakrzewski also serves on the board of a number of privately held companies, is the founder of a number of biotechnology companies, and is involved in a number of philanthropic activities. He was Chairman and CEO of Amarin Pharmaceuticals, a publicly traded company focused on the development and commercialization of cardiovascular drugs based on Omega 3‘s from 2010 to 2013, successfully developing and launching Vascepa®. Mr. Zakrzewski served as a Venture Partner with Orbimed, in 2010 and 2011. Prior to this, he was Chairman, President & Chief Executive Officer of Xcellerex, a privately held company focusing on commercializing its proprietary next generation manufacturing technology for biotherapeutics and vaccines from 2007 to 2010. Xcellerex was sold to GE Healthcare. Mr. Zakrzewski also served as the Chief Operating Officer of Reliant Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular drugs from 2005 to 2007. Mr. Zakrzewski had responsibility for the company’s pharmaceutical operations including, R&D, business development, supply chain/manufacturing, quality, IT, and compliance. Reliant Pharmaceuticals was sold to GlaxoSmithKline in 2007. Prior to this, Mr. Zakrzewski served in a variety of executive level capacities at Eli Lilly & Company for 17 years including R&D, manufacturing, finance and business development. His most recent position, Senior Vice President, had global responsibility for all business and corporate development. Mr. Zakrzewski, an inventor on multiple US patents, received a BS in Chemical Engineering from Drexel University in 1986, an MS in Biochemical Engineering from Drexel University in 1988, and an MBA in Finance in 1992 from Indiana University.

Acceleron Pharma, Amarin, Cerecin, Cyteir Therapeutics, and Sangamo Therapeutics

Name

Joe Zakrzewski

Firm

Work History

Mr. Zakrzewski has over 25 years of experience as an executive in the biotechnology and pharmaceutical industry. He currently serves on the Board of Directors of publicly held companies Acceleron Pharmaceuticals, Amarin Pharmaceuticals, Onxeo S.A., and Sangamo Therapeutics. Mr Zakrzewski also serves on the board of a number of privately held companies, is the founder of a number of biotechnology companies, and is involved in a number of philanthropic activities. He was Chairman and CEO of Amarin Pharmaceuticals, a publicly traded company focused on the development and commercialization of cardiovascular drugs based on Omega 3‘s from 2010 to 2013, successfully developing and launching Vascepa®. Mr. Zakrzewski served as a Venture Partner with Orbimed, in 2010 and 2011. Prior to this, he was Chairman, President & Chief Executive Officer of Xcellerex, a privately held company focusing on commercializing its proprietary next generation manufacturing technology for biotherapeutics and vaccines from 2007 to 2010. Xcellerex was sold to GE Healthcare. Mr. Zakrzewski also served as the Chief Operating Officer of Reliant Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular drugs from 2005 to 2007. Mr. Zakrzewski had responsibility for the company’s pharmaceutical operations including, R&D, business development, supply chain/manufacturing, quality, IT, and compliance. Reliant Pharmaceuticals was sold to GlaxoSmithKline in 2007. Prior to this, Mr. Zakrzewski served in a variety of executive level capacities at Eli Lilly & Company for 17 years including R&D, manufacturing, finance and business development. His most recent position, Senior Vice President, had global responsibility for all business and corporate development. Mr. Zakrzewski, an inventor on multiple US patents, received a BS in Chemical Engineering from Drexel University in 1986, an MS in Biochemical Engineering from Drexel University in 1988, and an MBA in Finance in 1992 from Indiana University.

Other Seats

Acceleron Pharma, Amarin, Cerecin, Cyteir Therapeutics, and Sangamo Therapeutics

AN2 Therapeutics Management Team

3 Team Members

AN2 Therapeutics has 3 executives. AN2 Therapeutics's founder is Joe Zakrzewski. AN2 Therapeutics's current Founder, Chief Executive Officer is Eric E. Easom.

Name

Work History

Title

Status

Eric E. Easom

Founder, Chief Executive Officer

Current

Joe Zakrzewski

Founder

Current

Paul Eckburg

Chief Marketing Officer

Current

Name

Eric E. Easom

Joe Zakrzewski

Paul Eckburg

Work History

Title

Founder, Chief Executive Officer

Founder

Chief Marketing Officer

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.